VC-backed Fusion Pharmaceuticals seeks $125m from IPO: report
Canadian cancer radiotherapeutics specialist Fusion Pharmaceuticals is looking to raise US$125 million (C$170 million) from its initial public offering on Nasdaq.
Canadian cancer radiotherapeutics specialist Fusion Pharmaceuticals is looking to raise US$125 million (C$170 million) from its initial public offering on Nasdaq.
Copyright PEI Media
Not for publication, email or dissemination